Literature DB >> 3191663

Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise.

L Gullestad1, L O Dolva, E Søyland, J Kjekshus.   

Abstract

Limiting factors of maximal exercise performance are not clearly defined. In order to differentiate between various factors, maximal exercise was studied during continuous (n = 12) and intermittent (n = 9) exercise. The non-selective beta-blocker timolol (10 mg b.i.d. for 5 days) was compared double-blind and placebo controlled with the beta-1-selective beta-blocker metoprolol (100 mg b.i.d. for 5 days), with respect to effect on maximal exercise tolerance. Total cumulated work was comparable during continuous and intermittent exercise. Timolol and metoprolol reduced maximal exercise performance. No difference was observed between the two beta-blockers during intermittent exercise. The non-selective beta-blocker caused a greater reduction in exercise performance (10.4%) than the beta-1-selective beta-blocker (4.7%) (P less than 0.05) during continuous exercise. Maximal heart rate was higher with metoprolol than timolol during continuous exercise. The non-selective beta-blocker caused a slightly greater inhibition of lipolysis than the beta-1 selective one. No significant differences in glucose concentrations were observed between the treatment regimens. Exercise caused a marked increase in serum potassium concentrations. Beta-blockade caused further increase in potassium at any given workload. This study indicates that maximal working capacity is comparable during continuous and intermittent exercise. Beta-1-selective and non-selective beta-blockade reduce the maximal working capacity, non-selective more than beta-1-selective. Substrate availability was not responsible for the beta-blocker induced reduction of the working capacity. The rate of rise in serum potassium was significantly higher during beta-blockade and may, therefore, be a limiting factor for the maximal working capacity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3191663     DOI: 10.1111/j.1475-097x.1988.tb00214.x

Source DB:  PubMed          Journal:  Clin Physiol        ISSN: 0144-5979


  5 in total

1.  The effects of beta1-adrenergic blockade on cardiovascular oxygen flow in normoxic and hypoxic humans at exercise.

Authors:  Guido Ferretti; Marc J Licker; Sara Anchisi; Christian Moia; Davide Susta; Denis R Morel
Journal:  Eur J Appl Physiol       Date:  2005-10-01       Impact factor: 3.078

2.  Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study.

Authors:  Matthew A Weir; David N Juurlink; Tara Gomes; Muhammad Mamdani; Daniel G Hackam; Arsh K Jain; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

3.  Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men.

Authors:  L Gullestad; K Birkeland; G Nordby; S Larsen; J Kjekshus
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

4.  Functional capacity in healthy volunteers before and following beta-blockade with controlled-release metoprolol.

Authors:  P K Rønnevik; J E Nordrehaug; G von der Lippe
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study.

Authors:  Johannes T H Nielen; Frank de Vries; Jeroen H P M van der Velde; Hans H C M Savelberg; Nicolaas C Schaper; Pieter C Dagnelie; Ronald M A Henry; Miranda Schram; Coen D A Stehouwer; Annelies Boonen; Annemarie Koster; Bart J F van den Bemt
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-05-24       Impact factor: 2.457

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.